Using Inflammatory Plasma Biomarkers to Predict Preclinical Alzheimer’s Disease
Haley Leclerc, Jessica Alber, Zachary J Kunicki, Sid E O'Bryant, Athene KW Lee · 2025
Read Using Inflammatory Plasma Biomarkers to Predict Preclinical Alzheimer’s Disease by Haley Leclerc, Jessica Alber, Zachary J Kunicki, Sid E O'Bryant, Athene KW Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715393.txt.
Description
Haley Leclerc and co-authors tested whether blood signs of swelling can flag silent Alzheimer's disease. Blood tests for the disease now work well once signs show. They are less sure in the stage where amyloid builds up but thought stays sharp. Swelling in the body has long been tied to the disease, so the team gave those signs a fair trial.
The group drew on one hundred twenty-five older adults with no thought loss. Each gave blood and had a brain scan for amyloid. The team ran the blood through a panel of twenty-one swelling-linked proteins, plus core disease signs. Five swelling signs sorted scan results best, but only with fair skill. Once age, schooling, sex, genes, and core signs were in the mix, the swelling signs added nothing. The core blood signs remain the ones to trust for this early stage.
Catalog record
| CREATOR | Haley Leclerc, Jessica Alber, Zachary J Kunicki, Sid E O'Bryant, Athene KW Lee |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |